You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Medical Images HTML and Clinical Trial Remote Collaboration
SBC: HEART IMAGING TECHNOLOGIES, LLC Topic: NHLBIDESCRIPTION provided by applicant Medical drugs and devices are regulated by the U S Food and Drug Administration FDA based on data from multicenter clinical trials In U S spending on clinical trials was approximately $ billion Over the past decade the efficiency of clinical trials has been improved by electronic data capture EDC systems whose use has increased from to ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma
SBC: Annias Immunotherapeutics, Inc. Topic: NCIDESCRIPTION provided by applicant Malignant primary brain tumors represent the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma Glioblastoma GBM is uniformly lethal and current therapy is non specific and produces a median overall survival of andlt months In contrast immunotherapeutic approaches are exq ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel method for inhibiting diabetic retinopathy
SBC: CMP Tarnhelm Partners Topic: NDESCRIPTION provided by applicant The long term objective of this project study is to develop a monoclonal antibody that inhibits the progression of diabetic retinopathy Insulin like growth factor I IGF I has been implicated in both endothelial dysfunction as well as the proliferative phase of the disease but IGF I concentrations in retina are not increased During hyperglycemia IGF I activa ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Ion Implantation Processes in AlN for Wide Bandgap Power Devices
SBC: ADROIT MATERIALS, INC. Topic: 02aCurrent and next-generation power systems require power devices that operate at high voltages and high frequencies beyond the reliable operating limit of the present silicon- and silicon carbide- based power devices. The material properties of AlN permit power devices to operate at these extremes, promoting device shrinkage for automotive applications as well as faster switching and more efficient ...
STTR Phase II 2015 Department of Energy -
Optical Waveguide Cross-Correlator for Attosecond Timing Synchronization
SBC: ADVR, INC. Topic: 32cThis Phase II STTR will develop a precision balanced optical cross-correlator using engineered nonlinearoptical waveguides. The proposed device will be important for future advances at large scale accelerator facilities by providing a means to achieve long-term sub-femtosecond timing and synchronization of all of a facilitys optical and RF sub-systems over fiber optic links. Statement of how this ...
STTR Phase II 2015 Department of Energy -
Development Of A Nanomaterial Anode For A Low Voltage Proportional Counter For Neutron Detection
SBC: NanoTechLabs Inc. Topic: 39hThe objective of this technology transfer effort is to leverage technology developed by our partner to produce a high efficiency, carbon nanotube array enhanced, portable proportional counter for neutron detection. We will develop a portable proportional counter for neutron detection utilizing nanostructured field emitters. Unlike traditional proportional counters, which are typically arranged in ...
STTR Phase II 2015 Department of Energy -
Developing therapeutic inhibitors of CIB1 for breast cancer
SBC: Reveris Therapeutics Topic: 102DESCRIPTIONprovided by applicantBreast cancer is the most common malignancy in women living in the USwith more thannew cases diagnosed each yearand an estimatedwomen dying from the disease inGreater thanof these diagnoses are classified as triple negative breast cancerTNBCwhich is considered among the most aggressive breast cancer sub typeswith the worst prognosisTNBC is difficult to treat because ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides
SBC: Initos Pharmaceuticals LLC Topic: 999DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecule ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
N/A
SBC: Generx+, Inc. Topic: N/AN/A
STTR Phase II 2000 Department of Health and Human ServicesNational Institutes of Health -
Contraceptive testing for semen availability in male monkeys
SBC: EPPIN PHARMA INC Topic: NICHDDESCRIPTION provided by applicant The global contraceptives market was valued at $ billion in and is expected to grow at a CAGR of from to to reach an estimated value of $ billion in An important high impact driver of this market is the prevalence of unintended pregnancies In the US there are million unintended pregnancies annually through inconsistent or ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health